Barnaby Hunt

1.4k total citations
85 papers, 1.1k citations indexed

About

Barnaby Hunt is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Barnaby Hunt has authored 85 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Endocrinology, Diabetes and Metabolism, 37 papers in Molecular Biology and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Barnaby Hunt's work include Diabetes Treatment and Management (75 papers), Diabetes Management and Research (54 papers) and Metabolism, Diabetes, and Cancer (37 papers). Barnaby Hunt is often cited by papers focused on Diabetes Treatment and Management (75 papers), Diabetes Management and Research (54 papers) and Metabolism, Diabetes, and Cancer (37 papers). Barnaby Hunt collaborates with scholars based in Denmark, United Kingdom and United States. Barnaby Hunt's co-authors include William J. Valentine, Samuel J. P. Malkin, J Langer, Barrie Chubb, Stephen C. Bain, Richard F. Pollock, Pierre Johansen, Michelle Mocarski, Åsa Ericsson and Antonio Ramírez de Arellano and has published in prestigious journals such as Breast Cancer Research and Treatment, BMJ Open and Diabetic Medicine.

In The Last Decade

Barnaby Hunt

82 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Barnaby Hunt Denmark 19 888 369 137 135 133 85 1.1k
Jennie H. Best United States 18 642 0.7× 244 0.7× 200 1.5× 64 0.5× 61 0.5× 40 1.0k
Panpan Wang China 9 242 0.3× 117 0.3× 142 1.0× 53 0.4× 60 0.5× 19 663
Arjan J. Kwakernaak Netherlands 19 180 0.2× 144 0.4× 233 1.7× 26 0.2× 77 0.6× 45 991
Antonio Nicolucci Italy 11 289 0.3× 321 0.9× 185 1.4× 15 0.1× 58 0.4× 16 881
Kyung Hee Yi South Korea 15 191 0.2× 206 0.6× 157 1.1× 27 0.2× 76 0.6× 28 1.0k
Björn Bolinder United States 11 514 0.6× 59 0.2× 76 0.6× 67 0.5× 127 1.0× 22 681
Peter Alperin United States 11 224 0.3× 108 0.3× 82 0.6× 59 0.4× 54 0.4× 14 518
Sophie Béliard France 19 257 0.3× 120 0.3× 377 2.8× 43 0.3× 32 0.2× 54 782
Moetaz Albizem United States 7 127 0.1× 80 0.2× 477 3.5× 115 0.9× 129 1.0× 9 1.0k
Josephina G. Kuiper Netherlands 13 154 0.2× 63 0.2× 87 0.6× 54 0.4× 110 0.8× 37 640

Countries citing papers authored by Barnaby Hunt

Since Specialization
Citations

This map shows the geographic impact of Barnaby Hunt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barnaby Hunt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barnaby Hunt more than expected).

Fields of papers citing papers by Barnaby Hunt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barnaby Hunt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barnaby Hunt. The network helps show where Barnaby Hunt may publish in the future.

Co-authorship network of co-authors of Barnaby Hunt

This figure shows the co-authorship network connecting the top 25 collaborators of Barnaby Hunt. A scholar is included among the top collaborators of Barnaby Hunt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barnaby Hunt. Barnaby Hunt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Malkin, Samuel J. P., et al.. (2025). The Long-Term Cost-Effectiveness of Oral Semaglutide Versus Lower-Cost Liraglutide in the UK. Diabetes Therapy. 16(4). 613–628.
2.
Alluhidan, Mohammed, et al.. (2024). Modeling the Clinical and Economic Burden of Therapeutic Inertia in People with Type 2 Diabetes in Saudi Arabia. Advances in Therapy. 41(11). 4140–4152. 1 indexed citations
3.
4.
5.
Viljoen, Adie, et al.. (2022). The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK. The European Journal of Health Economics. 24(6). 895–907. 5 indexed citations
6.
7.
Aksan, A, Alain Schoepfer, Pascal Juillerat, et al.. (2020). Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland. Advances in Therapy. 38(1). 660–677. 15 indexed citations
8.
9.
Yamada, T., Nobuhiro Shojima, Toshimasa Yamauchi, et al.. (2019). Clinical care and other categories posters: Incretin therapies. Diabetic Medicine. 36(S1). 134–135. 1 indexed citations
10.
Raya, Pedro Mezquita, Francisco Javier Ampudia‐Blasco, Barnaby Hunt, et al.. (2019). Evaluating the long‐term cost‐effectiveness of fixed‐ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real‐world clinical evidence. Diabetes Obesity and Metabolism. 21(6). 1349–1356. 14 indexed citations
11.
Bain, Stephen C., Brian Bekker Hansen, Barnaby Hunt, Barrie Chubb, & William J. Valentine. (2019). Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK. Journal of Medical Economics. 23(1). 98–105. 37 indexed citations
12.
Johansen, Pierre, Barnaby Hunt, Neeraj N. Iyer, Tam Dang‐Tan, & Richard F. Pollock. (2019). A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA. Advances in Therapy. 36(5). 1190–1199. 8 indexed citations
13.
Hunt, Barnaby, et al.. (2019). <p>Value For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In Italy</p>. ClinicoEconomics and Outcomes Research. Volume 11. 605–614. 9 indexed citations
14.
Wilkinson, Lars, Barnaby Hunt, Pierre Johansen, et al.. (2018). Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States. Diabetes Therapy. 9(3). 951–961. 16 indexed citations
15.
16.
17.
Barnett, Anthony, et al.. (2018). Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long‐term cost‐effectiveness analysis. Diabetes Obesity and Metabolism. 20(8). 1921–1927. 9 indexed citations
18.
Hunt, Barnaby, et al.. (2017). Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States. Journal of Medical Economics. 20(11). 1117–1120. 8 indexed citations
19.
Russell‐Jones, David, Simon Heller, Sarah Buchs, et al.. (2017). Projected long‐term outcomes in patients with type 1 diabetes treated with fast‐acting insulin aspart vs conventional insulin aspart in the UK setting. Diabetes Obesity and Metabolism. 19(12). 1773–1780. 8 indexed citations
20.
Mezquita‐Raya, Pedro, et al.. (2017). Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain. Diabetes Therapy. 8(2). 401–415. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jennie H. Best Breakdown of academic impact, for papers by Panpan Wang Breakdown of academic impact, for papers by Arjan J. Kwakernaak Breakdown of academic impact, for papers by Antonio Nicolucci Breakdown of academic impact, for papers by Kyung Hee Yi Breakdown of academic impact, for papers by Björn Bolinder Breakdown of academic impact, for papers by Peter Alperin Breakdown of academic impact, for papers by Sophie Béliard Breakdown of academic impact, for papers by Moetaz Albizem Breakdown of academic impact, for papers by Josephina G. Kuiper
Rankless by CCL
2026